|
|
Stephanie
Land, PhD
Research
Associate Professor
Education
BS, University
of Texas at Austin
MS, University of Texas at Austin
PhD, Stanford University
Research Interests
My current research is in two areas: 1) cancer-related behavioral research, especially related to smoking, and 2) social network analysis. I am the Director for The Reduce Smoking and Exposure to Tobacco (ReSET) Center. I am also the statistician responsible for the Biobehavioral Medicine Program of the University of Pittsburgh Cancer Institute and the Behavioral and Health Outcomes Program at the National Surgical Adjuvant Breast and Bowel Project (NSABP). (Health Sciences Faculty Research Interests Project). I am an Associate Editor for the Journal of Clinical Oncology.
Selected Publications
(April, 2008 - June, 2009)
Primack, B.A., S.R. Land, and M.J. Fine, Adolescent smoking and volume of exposure to various forms of media. Public Health, 2008 Apr. 122(4): p. 379-389.
Cella, D., S.R. Land, C.H. Chang, R. Day, J.P. Costantino, N. Wolmark, and P.A. Ganz, Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. Breast Cancer Res Treat, 2008 Jun. 109(3): p. 515-26.
Pennathur, A., J.D. Luketich, R.J. Landreneau, J. Ward, N.A. Christie, M.K. Gibson, M. Schuchert, K. Cooper, S.R. Land, and C.P. Belani, Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm. Ann Thorac Surg, 2008 Jun. 85(6): p. 1930-6; discussion 1936-7.
Stabile, L.P., M.E. Rothstein, P. Keohavong, J. Jin, J. Yin, S.R. Land, S. Dacic, T.M. Luong, K.J. Kim, A.M. Dulak, and J.M. Siegfried, Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther, 2008 Jul. 7(7): p. 1913-22.
Ganz, P.A. and S.R. Land, Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause, 2008 July/August. 15(4): p. 797-803.
Wang, W., H.D. Edington, D.M. Jukic, U.N. Rao, S.R. Land, and J.M. Kirkwood, Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma. Cancer Immunol Immunother, 2008 Sep. 57(9): p. 1315-21.
Land, S.R., J. Abrams, M. Buyse, and R.J. Chappell, Statistics in oncology. J Clin Oncol, 2008 Aug 1. 26(22): p. 3668.
Fourcade, J., P. Kudela, P.A. Andrade Filho, B. Janjic, S.R. Land, C. Sander, A. Krieg, A. Donnenberg, H. Shen, J.M. Kirkwood, and H.M. Zarour, Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother, 2008 Oct. 31(8): p. 781-91.
Land, S.R., Missing patient-reported outcome data in an adjuvant lung cancer study. J Clin Oncol, 2008 Nov 1. 26(31): p. 5018-9.
Jacobs, S.A., S.H. Swerdlow, J. Kant, K.A. Foon, R. Jankowitz, S.R. Land, N. DeMonaco, J. Joyce, J.L. Osborn, T.L. Evans, P.M. Schaefer, and T.M. Luong, Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res, 2008 Nov 1. 14(21): p. 7088-94.
Dacic, S., H. Kothmaier, S. Land, Y. Shuai, I. Halbwedl, P. Morbini, B. Murer, C. Comin, F. Galateau-Salle, F. Demirag, H. Zeren, R. Attanoos, A. Gibbs, P. Cagle, and H. Popper, Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch, 2008 Dec. 453(6): p. 627-35.
Land, S.R., ‘We all survived,’ and other failings of risk perception. Chance, 2008. 21(4).
Swain, S.M., S.R. Land, M.W. Ritter, J.P. Costantino, R.S. Cecchini, E.P. Mamounas, N. Wolmark, and P.A. Ganz, Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat, 2009 Jan. 113(2): p. 315-20 (Published online Feb 27, 2008).
Primack, B.A., B. Swanier, A.M. Georgiopoulos, S.R. Land, and M.J. Fine, Association between media use in adolescence and depression in young adulthood: a longitudinal study. Arch Gen Psychiatry, 2009 Feb. 66(2): p. 181-8.
Foon, K.A., M. Boyiadzis, S.R. Land, S. Marks, A. Raptis, L. Pietragallo, D. Meisner, A. Laman, M. Sulecki, A. Butchko, P. Schaefer, D. Lenzer, and A. Tarhini, Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol, 2009 Feb 1. 27(4): p. 498-503.
Zhang, G., X. Liu, A.M. Farkas, A.V. Parwani, K.L. Lathrop, D. Lenzner, S.R. Land, and H. Srinivas, Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol Endocrinol, 2009 Feb. 23(2): p. 146-56.
Styn, M.A., T. Nukui, M. Romkes, K. Perkins, S.R. Land, and J.L. Weissfeld, The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. Am J Med Genet B Neuropsychiatr Genet, 2009 Mar 5. 150B(2): p. 254-61 (Published online June 18, 2008).
Fourcade, J., P. Kudela, Z. Sun, H. Shen, S.R. Land, D. Lenzner, P. Guillaume, I.F. Luescher, C. Sander, S. Ferrone, J.M. Kirkwood, and H.M. Zarour, PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol, 2009 May 1. 182(9): p. 5240-9.
Hershberger, P.A., L.P. Stabile, B. Kanterewicz, M.E. Rothstein, C.T. Gubish, S. Land, Y. Shuai, J.M. Siegfried, and M. Nichols, Estrogen receptor beta (ERbeta) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. J Steroid Biochem Mol Biol, 2009 May 18.
Ganz, P.A., S.R. Land, C. Antonio, P. Zheng, G. Yothers, L. Petersen, D.L. Wickerham, N. Wolmark, and C.Y. Ko, Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv, 2009 Jun 13.
Contact Information
One Sterling
Plaza
201 North Craig Street, Suite 350
Pittsburgh, PA 15213
Telephone: 412-383-2213
Facsimile: 412-383-1387
Email: Land at nsabp.pitt.edu
|
 |
